0

Hypertension and Heart Failure

Epidemiology, Mechanisms and Treatment, Updates in Hypertension and Cardiovascular Protection

Erschienen am 05.03.2024, 2. Auflage 2024
213,99 €
(inkl. MwSt.)

Lieferbar innerhalb 1 - 2 Wochen

In den Warenkorb
Bibliografische Daten
ISBN/EAN: 9783031393143
Sprache: Englisch
Umfang: xi, 535 S.
Einband: gebundenes Buch

Beschreibung

The second edition of this successful volume explains how hypertension affects 20-50% of the adult population in developed countries. Heart failure is the result of the hypertension's effects on the heart and it represents a growing public health problem. In this context the international scientific community is continuously struggling to develop better strategies in screening, diagnosing and treating hypertension and its deleterious effects. Thus, this field is continuously changing, with new important information being added constantly, and this is the reason this new edition has been decided. It will dedicate new chapters regarding the socio-economic burden of hypertension and the role of heart rate, endothelial dysfunction and uric acid in the progression from hypertension to heart failure. Moreover, it will offer an insight into both the intimate mechanisms of transition from hypertension to heart failure and into clinical practice advice on the prevention and treatment of heart failure in hypertensive population. A part of the book will be dedicated to diagnostics, comprising a chapter on new perspectives on multimodality imaging and a special chapter on diastolic dysfunction. The arrhythmic complications of hypertensive heart disease will be structured in 2 chapters on atrial fibrillation and ventricular arrhythmias respectively. New chapters will be added regarding hypertension and heart failure in special populations such as cancer patients, young patients, pregnancy and patients with a history of SARS-CoV2 infection.

Autorenportrait

Maria Dorobantu is Professor of Cardiology at the University of Medicine and Pharmacy Carol Davila Bucharest, Romania. She has a special interest in the assessment and treatment of heart failure and arterial hypertension and has been principal investigator of important trials. She is the President of the Romanian Society of Hypertension and the national coordinator of the SEPHAR studies (Study for the Evaluation of Prevalence of Hypertension and Cardiovascular Risk among the Adult Population of Romania). Between 2016-2018 she has been the chairperson of the Coronary Pathophysiology and Microcirculation Working Group of Europeam Society of Cardiology. Giuseppe Mancia is Professor Emeritus of the University of Milano and Head of the Hypertension Centre of the Instituto Clinico Universitario, Verano Brianza. He is President of the Italian Foundation on Ricerca e Innovazione su Ipertensione e Protezione Cardiovascolare, of the Foundation of the European Society of Hypertension (ESH) in Zurich and Chairman of the Educational Board of ESH. He is since many years in the list of the highly cited scientists (Thompson Reuters) and has in 2013 been regarded as one of the 400 most influential biomedical investigators in the world (EJCI 2013). Guido Grassi is Professor of Internal Medicine at the Dept. of Clinical Medicine of the University of Milano, director of the PhD course in "Hypertension and Cardiovascular Risk", and director of the Center of Clinical Physiology and Hypertension of the same university. He is member of the Scientific Council on Hypertension of the ESC, ESH and ISH. He is also member of the ESH/ESC Task Force Guidelines on the Management of Hypertension. He is Executive Editor of Journal of Hypertension, official Journal of the ISH and the ESH. Victor Voicu is currently fellow the and vice president of Romanian Academy and President of Medical Science Section of Romanian Academy. He is Professor of Department of Pharmacology, Toxicology and Clinical Psychopharmacology, Faculty of Medicine, University of Medicine and Pharmacy Carol Davila Bucharest. He is President of the Romanian Society of Therapeutics, Pharmacology and Clinical Toxicology, and coordinator of Drug Sciences Panel of the Executive Unit for Financing of Higher Education, Research, Development and Innovation (EUFHERDI). Prof. Voicu is correspondent member from abroad of French National Academy of Medicine.